- Home
- GNLX vs RCEL Comparison
GNLX vs RCEL Comparison
Compare GNLX & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- RCEL
- Stock Information
- Founded
- GNLX 2001
- RCEL N/A
- Country
- GNLX United States
- RCEL United States
- Employees
- GNLX N/A
- RCEL N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- GNLX Health Care
- RCEL Health Care
- Exchange
- GNLX Nasdaq
- RCEL Nasdaq
- Market Cap
- GNLX 128.0M
- RCEL 107.8M
- IPO Year
- GNLX 2023
- RCEL N/A
- Fundamental
- Price
- GNLX $5.85
- RCEL $3.78
- Analyst Decision
- GNLX Strong Buy
- RCEL Buy
- Analyst Count
- GNLX 4
- RCEL 5
- Target Price
- GNLX $19.75
- RCEL $11.80
- AVG Volume (30 Days)
- GNLX 350.8K
- RCEL 267.2K
- Earning Date
- GNLX 11-05-2025
- RCEL 11-06-2025
- Dividend Yield
- GNLX N/A
- RCEL N/A
- EPS Growth
- GNLX N/A
- RCEL N/A
- EPS
- GNLX N/A
- RCEL N/A
- Revenue
- GNLX N/A
- RCEL $72,401,000.00
- Revenue This Year
- GNLX N/A
- RCEL $19.96
- Revenue Next Year
- GNLX N/A
- RCEL $33.43
- P/E Ratio
- GNLX N/A
- RCEL N/A
- Revenue Growth
- GNLX N/A
- RCEL 20.59
- 52 Week Low
- GNLX $1.99
- RCEL $3.35
- 52 Week High
- GNLX $8.54
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- GNLX 45.83
- RCEL 41.59
- Support Level
- GNLX $4.34
- RCEL $3.36
- Resistance Level
- GNLX $6.12
- RCEL $4.03
- Average True Range (ATR)
- GNLX 0.85
- RCEL 0.25
- MACD
- GNLX -0.32
- RCEL 0.05
- Stochastic Oscillator
- GNLX 36.41
- RCEL 58.49
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.